Dose-response curves of seven targeted drugs (sorafenib, lenvatinib, regorafenib, apatinib, bevacizumab, pemigatinib, and ivosidenib) for all screened 376 organoids (from 116 patients). Data represent relative cell viability values, with DMSO-treated organoids used as control. Error bars represent means +- SD from at least triplicate experiments.
